首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

1038596

類風濕性關節炎的全球市場 (2021年版) :藥物的各類型，各治療，診斷，各地區，各國分析 - 市場考察、預測，COVID-19的影響 (2021年～2026年)

Global Rheumatoid Arthritis Market (2021 Edition) - Analysis By Drug Type (NSAIDs, DMARDs, Corticosteroids, Others), Treatment, Diagnosis, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)

出版日期: 2021年11月30日 | 出版商:

Azoth Analytics | 英文 220 Pages | 訂單完成後即時交付

價格

全貌
簡介
目錄

簡介

全球類風濕性關節炎的市場規模，2020年價值244億6,000萬美元。促進類風濕性關節炎的成長的主要原因，是老年人口增加。此外，幾個證據暗示著吸煙者類風濕性關節炎發病的風險高。

本報告提供全球類風濕性關節炎市場相關調查分析，市場規模與預測，各市場區隔的市場分析，各地區的市場分析，競爭情形等相關的系統性資訊。

全球類風濕性關節炎市場競爭模式:藥物的各類型
- NSAID (非類固醇消炎劑)
- DMARD (緩解疾病性抗風濕藥)
- 皮質類固醇
- 其他
全球類風濕性關節炎市場競爭模式:各治療
- 肌腱修復
- 關節固定
- 關節重建
- 其他
全球類風濕性關節炎市場競爭模式:各診斷
- CRP
- ESR
- 其他

第6章全球類風濕性關節炎市場:地區分析

全球類風濕性關節炎市場競爭模式:各地區

第7章南北美洲的類風濕性關節炎市場:市場區隔(藥物的各類型，各治療，各診斷)

第8章歐洲的類風濕性關節炎市場:分析(2016年～2026年)

第9章亞太地區的類風濕性關節炎市場:分析(2016年～2026年)

第10章全球類風濕性關節炎市場動態

促進因素
阻礙因素
趨勢

第11章市場魅力

全球類風濕性關節炎市場市場魅力表:藥物的各類型
全球類風濕性關節炎市場市場魅力表:各治療
全球類風濕性關節炎市場市場魅力表:各診斷
全球類風濕性關節炎市場市場魅力表:各地區

第12章競爭情形

主要的類風濕性關節炎企業的產品平台
市場佔有率分析

第13章企業分析

Merck KGaA
Sanofi
Eli Lilly Company
Amgen Inc.
Bristol-Mayor Squibb
F. Hoffman-La Roche Ltd
Johnson & Johnson
Cipla
Pfizer
Galapagos NV
Gilead Sciences

Executive Summary

The Global Rheumatoid Arthritis Market was valued at USD 24.46 Billion in the year 2020. Globally, the market for rheumatoid arthritis is increasing rapidly and the major factor that drives the growth of rheumatoid arthritis is the increasing ageing population. Furthermore, some evidence suggests that people who smoke are at an increased risk of developing rheumatoid arthritis.

DMARDs segment is expected to hold a significant share in the Rheumatoid Arthritis Market on the back of the increasing prevalence of rheumatoid arthritis incidences across the globe, the launch of the therapeutic agents, and the favourable reimbursement policies for the high-cost treatment products. These are the major factors propelling the growth of the market.

Americas region dominated the global Rheumatoid Arthritis market and led the industry in 2020 owing to the presence of a large patient base and availability of well-developed infrastructure, rising awareness regarding disease treatment, growing geriatric population, and high adoption of biopharmaceuticals for treatment.

There is also an increase in funds provided to academic research institutions and individual researchers that is expected to boost the market growth. Moreover, various initiatives by international bodies, such as WHO and NIH for the prevention and treatment of chronic disorders, such as cardiovascular diseases, Rheumatoid Arthritis and cancer are anticipated to facilitate the growth of the market.

Scope of the Report

The report presents the analysis of the Rheumatoid Arthritis market for the historical period of 2016-2020 and the forecast period of 2021-2026.
The report analyses the Rheumatoid Arthritis Market by Value (USD Million).
The report analyses the Rheumatoid Arthritis Market By Drug Type - NSAID(non-steroidal anti-inflammatory drugs), DMARDs (Disease-modifying anti-rheumatic drug), Corticosteroids, Others
The report analyses the Rheumatoid Arthritis Market by Treatment - Tendon Repair, Joint Fusion, Joint Replacement, Others.
The report analyses the Rheumatoid Arthritis Market By Diagnosis - CRP (Creative Protein Test), ESR (Erythrocyte Sedimentation Rate), Others.
The Global Rheumatoid Arthritis Market has been analysed by countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
Also, the attractiveness of the market has been presented by region, by Drug Type, by Treatment, By Diagnosis.
Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Merck KGaA, Sanofi, Eli Lilly Company, Amgen Inc., Bristol-Mayor Squibb, F. Hoffman-La Roche Ltd., Johnson & Johnson, Cipla, Pfizer, Galapagos NV, Gilead Sciences.

Key Target Audience

Pharmaceutical Companies
Consulting and Advisory Firms
Government and Policy Makers
Regulatory Authorities

1. Report Scope and Methodology

1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary

2. Strategic Recommendations

3. Rheumatoid Arthritis Market: Product Outlook

4. Global Rheumatoid Arthritis Market: Sizing and Forecast

4.1 Global Rheumatoid Arthritis Market Size, By Value, 2016-2026
4.2 Impact of COVID-19 on Global Rheumatoid Arthritis Market

5. Global Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis

5.1 Competitive Scenario of Global Rheumatoid Arthritis Market: By Drug Type
- 5.1.1 NSAID(non-steroidal anti-inflammatory drugs) - Market Size and Forecast (2016-2026)
- 5.1.2 DMARD'S(Disease-modifying anti-rheumatic drug) - Market Size and Forecast (2016-2026)
- 5.1.3 Corticosteroids- Market Size and Forecast (2016-2026)
- 5.1.4 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Rheumatoid Arthritis Market: By Treatment
- 5.2.1 Tendon Repair - Market Size and Forecast (2016-2026)
- 5.2.2 Joint Fusion- Market Size and Forecast (2016-2026)
- 5.2.3 Joint Replacement- Market Size and Forecast (2016-2026)
- 5.2.4 Others - Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Rheumatoid Arthritis Market: By Diagnosis
- 5.3.1 CRP(Creative Protein Test) - Market Size and Forecast (2016-2026)
- 5.3.2 ESR (Erythrocyte Sedimentation Rate)- Market Size and Forecast (2016-2026)
- 5.3.3 Others - Market Size and Forecast (2016-2026)

6. Global Rheumatoid Arthritis Market: Regional Analysis

6.1 Competitive Scenario of Global Rheumatoid Arthritis Market: By Region

7. Americas Rheumatoid Arthritis Market: Segmentation (By Drug Type, By Treatment, By Diagnosis)

7.1 Americas Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
7.2 Americas Rheumatoid Arthritis Market - Prominent Companies
7.3 Market Segmentation By Drug Type (DMARDis, NSAID, Corticosteroids and Others)
7.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)
7.5 Market Segmentation By Diagnosis (CRP, ESR and Others)
7.6 Americas Rheumatoid Arthritis Market: Country Analysis
7.7 Market Opportunity Chart of Americas Rheumatoid Arthritis Market - By Country, By Value, 2026
7.8 Competitive Scenario of Americas Rheumatoid Arthritis Market: By Country
7.9 United States Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
7.10 United States Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
7.11 Canada Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
7.12 Canada Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

8. Europe Rheumatoid Arthritis Market: An Analysis (2016-2026)

8.1 Europe Rheumatoid Arthritis Market: Size and Forecast (2016-2026)
8.2 Europe Rheumatoid Arthritis Market - Prominent Companies
8.3 Market Segmentation By Drug Type (DMARDis, NSAID, Corticosteroids and Others)
8.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)
8.5 Market Segmentation By Diagnosis (CRP, ESR and Others)
8.6 Europe Rheumatoid Arthritis Market: Country Analysis
8.7 Market Opportunity Chart of Europe Rheumatoid Arthritis Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Rheumatoid Arthritis Market: By Country
8.9 Germany Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.10 Germany Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8.11 United Kingdom Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8.13 France Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.14 France Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8.15 Italy Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.16 Italy Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
8.17 Spain Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
8.18 Spain Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

9. Asia Pacific Rheumatoid Arthritis Market: An Analysis (2016-2026)

9.1 Asia Pacific Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Rheumatoid Arthritis Market - Prominent Companies
9.3 Market Segmentation By Drug Type (DMARDs, NSAID, Corticosteroids and Others)
9.4 Market Segmentation By Treatment (Tendon Repair, Joint Fusion, Joint Replacement and Others)
9.5 Market Segmentation By Diagnosis (CRP, ESR and Others)
9.6 Asia Pacific Rheumatoid Arthritis Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Rheumatoid Arthritis Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Rheumatoid Arthritis Market: By Country
9.9 China Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
9.10 China Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
9.11 Japan Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
9.12 Japan Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)
9.13 India Rheumatoid Arthritis Market: Size and Forecast (2016-2026), By Value
9.14 India Rheumatoid Arthritis Market Segmentation - By Drug Type, By Treatment, By Diagnosis (2016-2026)

10. Global Rheumatoid Arthritis Market Dynamics

10.1 Drivers
10.2 Restraints
10.3 Trends

11. Market Attractiveness

11.1 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Drug Type, 2026
11.2 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Treatment, 2026
11.3 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Diagnosis, 2026
11.4 Market Attractiveness Chart of Global Rheumatoid Arthritis Market - By Region, 2026

12. Competitive Landscape

12.1 Product Pipeline of Leading Rheumatoid Arthritis Companies
12.2 Market Share Analysis

13. Company Analysis

13.1 Merck KGaA
13.2 Sanofi
13.3 Eli Lilly Company
13.4 Amgen Inc.
13.5 Bristol-Mayor Squibb
13.6 F. Hoffman-La Roche Ltd
13.7 Johnson & Johnson
13.8 Cipla
13.9 Pfizer
13.10 Galapagos NV
13.11 Gilead Sciences

List of Figures

Figure 1: Global Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Research and Development (% of GDP), 2015-2018
Figure 3: GDP per Capita Growth (annual %), 2015-2019
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 7: Global Rheumatoid Arthritis Market- By Drug Type Market Share, 2020 & 2026
Figure 8: Global Rheumatoid Arthritis Market- By NSAID, By Value (USD Million), 2016-2026
Figure 9: Global Rheumatoid Arthritis Market- By DMARDiS, By Value (USD Million), 2016-2026
Figure 10: Global Rheumatoid Arthritis Market- By Corticosteroids, By Value (USD Million), 2016-2026
Figure 11: Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Rheumatoid Arthritis Market- By Treatment Market Share, 2020 & 2026
Figure 13: Global Rheumatoid Arthritis Market- By Tendon Repair, By Value (USD Million), 2016-2026
Figure 14: Global Rheumatoid Arthritis Market- By Joint Fusion, By Value (USD Million), 2016-2026
Figure 15: Global Rheumatoid Arthritis Market- By Joint Replacement, By Value (USD Million), 2016-2026
Figure 16: Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026
Figure 17: Global Rheumatoid Arthritis Market- By Diagnosis Market Share, 2020 & 2026
Figure 18: Global Rheumatoid Arthritis Market- By CRP, By Value (USD Million), 2016-2026
Figure 19: Global Rheumatoid Arthritis Market- By ESR, By Value (USD Million), 2016-2026
Figure 20: Global Rheumatoid Arthritis Market- By Others, By Value (USD Million), 2016-2026
Figure 21: Global Rheumatoid Arthritis Market- By Region Market Share, 2020 & 2026
Figure 22: Americas Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 23: Americas Biologic medicine share of total pharmaceutical sales, 2018 (Share of sales in %)
Figure 24: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 25: North America Population ages 65 and above (% of total Population), 2016-2020
Figure 26: Americas Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 27: Americas Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 28: Americas Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 29: Market Opportunity Chart of Americas Rheumatoid Arthritis Market- By Country, By Value (2016-2026)
Figure 30: Americas Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026
Figure 31: United States Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 32: United States Current health expenditure per capita (current USD), 2014-18
Figure 33: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 34: United States Population aged 65 and above (% of total Population), 2016-2020
Figure 35: United States Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 36: United States Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 37: United States Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 38: Canada Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 39: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 40: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 41: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 42: Canada Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 43: Canada Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 44: Canada Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 45: Europe Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 46: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 47: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 48: European Countries Population ages 65 and above (% of total Population), 2020
Figure 49: Europe Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 50: Europe Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 51: Europe Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 52: Market Opportunity Chart of Europe Rheumatoid Arthritis Market- By Country, By Value (2016-2026)
Figure 53: Europe Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026
Figure 54: Germany Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 55: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 56: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 57: Germany Urban population, 2015-2019 (In %)
Figure 58: Germany Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 59: Germany Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 60: Germany Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 61: United Kingdom Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 62: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 63: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 64: United Kingdom Population ages 65 and above (% of total Population), 2016-20
Figure 65: United Kingdom Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 66: United Kingdom Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 67: United Kingdom Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 68: France Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 69: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 70: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 71: France Population ages 65 and above (% of Total Population), 2016-20
Figure 72: France Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 73: France Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 74: France Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 75: Italy Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 76: Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 77: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 78: Italy Population ages 65 and above (% of Total Population), 2016-20
Figure 79: Italy Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 80: Italy Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 81: Italy Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 82: Spain Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 83: Spain Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 84: Spain Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 85 Spain Urban population, 2016-2020 (In %)
Figure 86: Spain Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 87: Spain Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 88: Spain Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 89: Asia Pacific Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 90: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 91: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 92: Asia Pacific Population ages 65 and above, by Countries (% of Total Population), 2020
Figure 93: Asia Pacific Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 94: Asia Pacific Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 95: Asia Pacific Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 96: Market Opportunity Chart of APAC Rheumatoid Arthritis Market- By Country, By Value (Year-2026)
Figure 97: APAC Rheumatoid Arthritis Market- By Country Market Share, 2020 & 2026
Figure 98: China Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 99: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 100: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 101: China Population ages 65 and above (% of Total Population), 2016-20
Figure 102: China Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 103: China Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 104: China Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 105: Japan Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 106: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 107: Japan Current Healthcare Expenditure as a percentage of GDP, 2015-2018 (In %)
Figure 108: Japan Population ages 65 and above (% of Total Population), 2016-20
Figure 109: Japan Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 110: Japan Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 111: Japan Rheumatoid Arthritis Market- By Diagnosis, By Value (USD Million), 2016-2026
Figure 112: India Rheumatoid Arthritis Market Size, By Value, 2016-2026 (USD Million)
Figure 113: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 114: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 115: India Population ages 65 and above (% of Total Population), 2016-20
Figure 116: India Rheumatoid Arthritis Market- By Drug Type, By Value (USD Million), 2016-2026
Figure 117: India Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 118: India Rheumatoid Arthritis Market- By Treatment, By Value (USD Million), 2016-2026
Figure 119: Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Drug Type (2016-2026)
Figure 120: Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Treatment (2016-2026)
Figure 121: Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Diagnosis (2016-2026)
Figure 122: Market Attractiveness Chart of Global Rheumatoid Arthritis Market- By Region (2016-2026)
Figure 123: Global Rheumatoid Arthritis Market - Company Share (%), 2020
Figure 124: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 125: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 126: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 127: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 128: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 129: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 130: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 131: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 132: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 133: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Figure 134: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 135: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Figure 136: Amgen Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 137: Amgen Inc. Net Income, 2016-2020 (USD Million)
Figure 138: Amgen Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 139: Amgen Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 140: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 141: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 142: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 143: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 144: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 145: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 146: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 147: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 148: Johnson & Johnson Annual Sales Revenue (USD Billion), 2016-2020
Figure 149: Johnson & Johnson Annual Net Income/Loss (USD Billion), 2016-2020
Figure 150: Johnson & Johnson Sales Revenue Split, By Business Segment (%), FY2020
Figure 151: Johnson & Johnson Sales Revenue Split, By Geography Segment (%), FY2020
Figure 152: Cipla Sales Revenues, 2016-2020 (USD Million)
Figure 153: Cipla sales Revenues, By Business Segment (%), FY2020
Figure 154: Cipla sales Revenue, By Geographical Segment (%), FY2020
Figure 155: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 156: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 157: Pfizer sales Revenue, By Geographical Segment (%), FY2020
Figure 158: Galapagos NV Annual Sales Revenue (USD Million), 2016-2020
Figure 159: Galapagos NV sales Revenue, By Geographical Segment (%), FY2020
Figure 160: Gilead Sciences Annual Sales Revenue (USD Million), 2016-2020
Figure 161: Gilead Sciences Annual Net Income (USD Million), 2016-2019